LCM
TVTX icon

Laurion Capital Management’s Travere Therapeutics TVTX Stock Holding History

Laurion Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,157
Closed -$91.7K – 585
2024
Q2 		$91.7K Buy
+11,157
New +$75.1K ﹤0.01% 513
2023
Q2 		– Sell
-984,961
Closed -$22.2M – 699
2023
Q1 		$22.2M Buy
984,961
+150,000
+18% +$3.19M 0.15% 131
2022
Q4 		$17.6M Hold
834,961
– – 0.08% 181
2022
Q3 		$20.6M Hold
834,961
– – 0.12% 133
2022
Q2 		$20.2M Sell
834,961
-33,817
-4% -$850K 0.31% 69
2022
Q1 		$22.4M Sell
868,778
-40,173
-4% -$1.07M 0.27% 67
2021
Q4 		$28.2M Buy
908,951
+150,000
+20% +$4.22M 0.29% 60
2021
Q3 		$18.4M Buy
758,951
+191,768
+34% +$3.52M 0.08% 213
2021
Q2 		$8.28M Buy
567,183
+304,170
+116% +$6M 0.05% 235
2021
Q1 		$6.57M Buy
+263,013
New +$7.27M 0.04% 300
2015
Q3 		– Sell
-227,898
Closed -$7.55M – 907
2015
Q2 		$7.55M Sell
227,898
-192,779
-46% -$5.28M 0.07% 236
2015
Q1 		$10.1M Buy
420,677
+233,498
+125% +$3.56M 0.2% 118
2014
Q4 		$2.29M Buy
+187,179
New +$1.94M 0.05% 123

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Laurion Capital Management's TVTX Position: Q3 2024 in Review

Laurion Capital Management sold out of Travere Therapeutics (TVTX) in Q3 2024, closing a stake of 11,157 shares — an estimated $91.7K sold.

Laurion Capital Management first reported a position in TVTX in Q4 2014 and held it in 13 quarters. The position peaked at $28.2M in Q4 2021. 178 funds tracked by Wall St. Rank hold TVTX as of Q3 2024.

  • Laurion Capital Management reported no remaining Travere Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Laurion Capital Management sold 11,157 Travere Therapeutics shares in Q3 2024, an estimated $91.7K.
  • Laurion Capital Management first reported a position in Travere Therapeutics in Q4 2014 and held it in 13 quarters.
  • Laurion Capital Management's Travere Therapeutics position peaked at $28.2M in Q4 2021.
  • 178 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.